ISSN 2490-3329 (Print)
ISSN 2303-7954 (Online)

Volume 49, Issue 1, Article 1

(Scr Med 2018:49:6-12)
ORIGINAL ARTICLE

Relationship between Atrial Fibrillation as a Risk Factor and the Outcome of Ischemic Stroke

Siniša Miljković1, Andrej Blagojević2, Tamara Petrušić3

1 Clinic of Neurology, UCC of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina
2 Institute for Physical Medicine and Rehabilitation “Dr Miroslav Zotović”, Banja Luka, Bosnia and Herzegovina
3 Inpharm Co LTD, Banja Luka, Bosnia and Herzegovina


doi: 10.18575/msrs.sm.e.18.01
UDC: 616.831-005.1
COBISS.RS-ID: 7315992


ABSTRACT

Introduction: Atrial fibrillation is characterized by uncoordinated atrial activity with consequent deterioration of mechanical function. Patients have 5 times more risk for stroke. These stokes are more severe, more disabling and have a more frequent fatal outcome.

Aim of the Study: The aim was to examine the relationship between atrial fibrillation as risk factor and ischemic stroke. 

Patients and Methods: Prospective cohort study was conducted at the Clinic of Neurology, UCC of the Republic of Srpska during the period from January to March 2017. The study included 138 patients who survived ischemic stroke, and atrial fibrillation was identified as a risk factor. Severity of stroke was assessed on admission and discharge with NIHS Scale, and level of disability with Rankin scale. Data was collected and analysed in softwere programe IBM SPSS Statistics 21.

Results: The sample consisted of 138 patients with ischemic stroke, divided into two groups, with  ischemic stroke and atrial fibrillation, and without atrial fibrillation. There were 55.1% male, and 44.9% female patients. Atrial fibrillation was more common in female patients (46.8%) than in male patients (30.3%), and there was a significant relationionship between gender and atrial fibrillation (χ2(1, N = 138) = 3.29, p = 0.07). It was most common in the oldest age group. There was no significant relationship between fatal outcome and atrial fibrillation, gender and age.

Conclusion: Recovery of stoke patients with this comorbidity is much more difficult and slower compared to patients without atrial fibrillation. Early detection and use of oral anticoagulant therapy can significantly decrease stroke risks, and also ease the consequences when stroke already happened.

Key words: stroke, atrial fibrillation, fatal outcome

 


Pdf version of article


Reference:
1. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257-354. https://doi.org/10.1161/CIRCULATIONAHA.106.177292  PMid:16908781
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-5.  https://doi.org/10.1001/jama.285.18.2370  PMid:11343485
3. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215. https://doi.org/10.1161/CIRCULATIONAHA.109.192667  PMid:20019324
4. Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113(5):359-64. PMID: 12401529. https://doi.org/10.1016/S0002-9343(02)01236-6
5. Lee WC, Lamas GA, Balu S, et al. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J Med Econ. 2008;11(2):281-98. PMID: 19450086.
6. Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care. 2004;10(14 Suppl):S451-58; discussion S8-61. PMID: 15696909.
7. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996;2 (10):1760-4.  https://doi.org/10.1161/01.STR.27.10.1760  PMid:8841325
8. Atrial-Fibrillation-Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154 (13):144957. https://doi.org/10.1001/archinte.154.13.1449 https://doi.org/10.1001/archinte.1994.00420130036007  PMid:8018000
9. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebocontrolled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1(8631):175–9. https://doi.org/10.1016/S0140-6736(89)91200-2
10. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–47. https://doi.org/10.1093/eurheartj/ehs253  PMid:22922413
11. Deplanque D, Leys D, et al. Secondary Prevention of Stroke in Patients with Atrial Fibrillation: Factors Influencing the Prescription of Oral Anticoagulation at Discharge. Cerebrovasc Dis 2006;21(56): 372–379. https://doi.org/10.1159/000091546  PMid:16490950
12. Gallagher AM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost. 2008;6(9):1500–6. https://doi.org/10.1111/j.1538-7836.2008.03059.x  PMid:18573187
13. Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, Parker CS, Price M, Metlay JP, Cohen A, et al. Can we predict daily adherence to warfarin?: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Chest. 2010;137(4):883–9. https://doi.org/10.1378/chest.09-0039  PMid:19903973 PMCid:PMC2851552
14. Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A, Meeder JG, Prins MH, Lévy S, Crijns HJ; Euro Heart Survey Investigators.Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation: the Euro Heart Survey on Atrial Fibrillation. Am Heart J. 2007;153:1006–1012. https://doi.org/10.1016/j.ahj.2007.03.008
15. Potpara TS, Trendafilova E, Dan G-A, et al. The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey. Advances in Therapy. 2017;34(8):2043-2057. https://doi:10.1007/s12325-017-0589-5


Contact address:
Siniša Miljković
Clinic of Neurology, University
Clinical Centre of the Republic of
Srpska
Street address: Dvanaest Beba bb,
78 000 Banja Luka,
Republic of Srpska
Bosnia and Herzegovina
e-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
phone number: +387-51-342-548

Submitted: February 9th, 2018
Accepted: February 27th, 2018